Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

Author： Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.31, Iss.6, 2013-12, pp. : 1399-1408

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-01 ,pp. : 3048-3056

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?

By  

Current Medicinal Chemistry, Vol. 18, Iss. 36, 2011-12 ,pp. : 5528-5544

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 2047-2059

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 126-142

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite